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Abstract
Aim: To conduct a meta-analysis and systematic review to examine the effects of
glucagon-like peptide-1 receptor agonists (GLP-1RAs) on clinical biomarkers of
inflammation and oxidative stress in patients with type 2 diabetes.
Methods: Medline, Embase and the Cochrane Library were searched for randomised
controlled trials (RCTs) that examined changes with GLP-1RAs in a priori selected
biomarkers of inflammation: C-reactive protein (CRP), adiponectin, tumour necrosis
factor-alpha (TNFα), plasminogen activator inhibitor-1, interleukin-6, leptin; and of
oxidative stress: malondialdehyde (MDA); 8-iso-prostaglandin F2α; and 8-hydroxy-
20-deoxyguanosine (8-OHdG).
Results: We included 40 eligible RCTs (n = 6749) with a median follow-up of
6 months, a mean participant age of 53.1 years, 56.3% females, glycated
haemoglobin (HbA1c) 55.6 mmol/mol, body mass index 28.8 kg/m2 and diabetes
duration 7.46 years. Analysis of GLP-1RAs versus standard diabetes therapies or pla-
cebo revealed significant reductions in CRP, TNFα and MDA, and significant
increases in adiponectin for (mean difference 0.54 mg/L [0.75, 0.34]; standard
mean difference [SMD] 0.39 [0.62, 0.15]; SMD 0.84 [1.61, 0.06] and SMD
0.30 [0.12, 0.49], respectively [95% confidence intervals]). Systolic blood pressure
decreased significantly and was significantly and strongly correlated with a reduction
in CRP. Homeostatic model assessment of insulin resistance was also significantly
correlated with a reduction in CRP, but HbA1c was not.
Conclusions: There is strong evidence supporting clinically relevant anti-
inflammatory and antioxidant effects of GLP-1RAs. This may be used to guide future
targeted clinical use of GLP-1RAs and the development of medications seeking to
target the cardioprotective properties of GLP-1RAs.
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1 | INTRODUCTION
Type 2 diabetes mellitus (T2DM) leads to significant macro- and
microvascular complications. T2DM is associated with a doubling in
the risk of cardiovascular complications1 and is the leading cause of
chronic kidney disease worldwide.2 There is evidence to implicate
inflammation and oxidative stress in the pathogenesis of T2DM and
associated cardiovascular and renal complications. Furthermore, acute
phase reactants and proinflammatory cytokines, such as C-reactive
protein (CRP) and interleukin-6 (IL-6) predict the development of
T2DM in addition to the risk of complications.3,4 Elevated circulating
concentrations of inflammatory biomarkers are consistently found in
people with T2DM.5,6 Indeed, cardiovascular events in individuals
with T2DM are associated with raised CRP and are inversely related
to adiponectin levels.7–9 Similarly, concentrations of 8-iso-
prostaglandin F2α (8-iso-PGF2α), malondialdehyde (MDA), and
8-hydroxy-20-deoxyguanosine (8-OHdG) biomarkers have been found
to be elevated in patients with T2DM compared to healthy controls in
both serum10–12 and urine.13–15 Furthermore, within T2DM cohorts,
higher levels of oxidative stress biomarkers are associated with
increased cardiovascular15 and renal disease risk.16 Additional data
also support a role for inflammation and oxidative stress in the patho-
genesis of nonalcoholic fatty liver disease (NAFLD), which affects over
two-thirds of those with T2DM.17 Serum levels of adiponectin are
low in patients with T2DM presenting with liver disease,18 and the
severity of liver disease appears to be correlated with inflammatory
biomarkers such as tumour necrosis factor-alpha (TNFα)19 and IL-6.20
Markers of oxidative stress are also higher in T2DM patients with
nonalcoholic steatohepatitis as compared with T2DM patients with-
out liver disease.21
During the past decade, studies have suggested that glucagon-like
peptide-1 receptor agonists (GLP-1RAs) exhibit cardiorenal protective
properties. Major cardiovascular trials in patients with T2DM, includ-
ing the LEADER, SUSTAIN-6, HARMONY Outcomes and REWIND
trials,22–25 have collectively demonstrated a significant reduction in
cardiovascular death with GLP-1RA therapy, ranging from 12% to
26%. The LEADER and REWIND trials also report a greater than 20%
reduction in the risk of developing new macroalbuminuria, along with
favourable trends in other clinically relevant adverse renal out-
comes.26,27 Sodium-glucose cotransporter-2 (SGLT2) inhibitors have
similar cardiorenal protective properties and we have recently
described that SGLT2 inhibitors reduce biomarkers of inflammation
and oxidative stress.28 Although a number of mechanisms have been
proposed, it is unclear how GLP-1RAs exert their cardiorenal protec-
tive effects in patients with T2DM and whether an impact on inflam-
mation and oxidative stress may contribute. This meta-analysis and
systematic review of randomised trials aims to examine the effect of
GLP-1RAs on inflammatory and oxidative stress biomarkers in clinical
practice.
2 | METHODS
This review is reported in line with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) statement and reg-
istered with PROSPERO (CRD42020182116).
2.1 | Search strategy
We searched Medline, Embase, and the Cochrane Library up to April
2020 using the following search terms limited to humans: (glucagon-
like peptide-1 receptor agonist OR ([GLP1 OR GLP-1] AND [receptor
agonist OR analog*]) OR GLP 1RA* OR GLP 1 RA* OR incretin
mimetic* OR specific drug names) AND (C-reactive protein OR
adiponectin OR leptin OR interleukin 6 OR tumour necrosis factor-
alpha OR vascular cell adhesion protein/ oxidative stress). The
detailed search strategy is provided in Tables S1A and S1B, and is
available on PROSPERO. Medical Subject Heading terms were used in
most cases. Following the search and removal of duplicates, two
reviewers screened titles (J.J.H.B. and H.F.D.) and abstracts for rele-
vance, before assessing full texts for inclusion eligibility (Figure 1).
2.2 | Study selection
Only prospective randomised controlled trials (RCTs) were included,
of either parallel or crossover design. Observational studies and arti-
cles without original data in human participants were excluded. Our
study population of interest was adults with impaired glucose toler-
ance (prediabetes and type 2 diabetes mellitus). We excluded studies
that included participants aged less than 18 years or with type 1 diabe-
tes mellitus. Only studies with biomarker outcomes that could be
compared through meta-analysis or
control-subtracted mean were included. Despite having very similar
results, Fan et al,30 2013 and Tian et al,31 2018 were considered dif-
ferent studies as they were conducted in different Chinese hospitals
and had different baseline characteristics.
2.3 | Outcomes of interest and comparisons
Our biomarkers of interest were selected a priori and included, for
inflammation: CRP, adiponectin, leptin, IL-6, TNFα, vascular cell
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adhesion protein-1 (VCAM1) and plasminogen activator inhibitor-1
(PAI-1), and for oxidative stress: 8-iso-PGF2α, 8-OHdG, oxidised low-
density lipoprotein (ox-LDL) and MDA. These were selected as they
are widely accepted and reported biomarkers, with clear significance
and validity.
For each biomarker, comparisons were made between study arms
exposed to GLP-1RAs and control therapies. Subgroup analysis was
undertaken to compare GLP-1RAs with (a) placebo, (b) diabetes medi-
cations and (c) insulin. Comparison of GLP-1RAs versus all three sub-
groups is referred to as ‘Total’. VCAM1 and ox-LDL were excluded
due to insufficient data.
2.4 | Data extraction and synthesis
Three reviewers (J.J.H.B., H.F.D. and A.L.H.) independently transferred
raw data from selected papers into preformatted tables. Continuous
outcomes were converted into equivalent units for each biomarker.
Patient characteristics were obtained and are shown in Table 1.
Follow-up data for GLP-1RA-exposed and control groups were taken
in combination with standard deviations (SDs) and used to construct
forest plots for the following biomarkers: CRP (Figure 2A); adiponectin
(Figure 2B); TNFα (Figure 2C); IL-6 (Figure 2D); leptin (Figure 2E);
PAI-1 (Figure 2F); serum MDA (Figure 2G); serum 8-iso-PGF2a
(Figure 2H), and urinary 8-OHdG (Figure 2I). In order to analyse the
comparison of change from baseline to follow-up between GLP-1RAs
and control groups, we produced control-subtracted change from
baseline values. To allow for differences in measurement techniques,
these control-subtracted change data were converted to control-
subtracted percentage change from GLP-1RAs at baseline (Table S4).
Control-subtracted mean change statistics were analysed in con-
junction with P values from statistical tests comparing GLP-1RAs at
baseline and follow-up, and where this was not available between
GLP-1RAs and control.
F IGURE 1 Flow diagram based on the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist29 showing
resulting articles found and reasons for exclusion
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F IGURE 2 Forest plots showing the effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) compared to other diabetes therapy
(Total), and subgroup comparisons: GLP-1RA versus (A) placebo, (B) diabetes medications, and (C) insulin. The following biomarkers are shown:
(A) C-reactive protein, (B) adiponectin, (C) tumour necrosis factor α, (D) plasminogen activator inhibitor-1, (E) leptin, (F) interleukin-6, (G) serum
8-iso-prostaglandin F2α (8-iso-PGF2α), (H), malondialdehyde, (I) urinary 8-hydroxy-20-deoxyguanosine. †Imputed values70
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2.5 | Associations with biomarker changes and
other clinically relevant outcomes
Raw data were collected on other clinically relevant variables to
examine whether changes in biomarkers were associated with
changes in clinically meaningful variables. In this respect, control-
subtracted percentage changes were produced to compare propor-
tional changes in the following variables with relevant biomarkers:
body weight, body mass index (BMI), glycated haemoglobin (HbA1c),
fasting glucose, 120-minute postprandial glucose, homeostatic
model assessment of insulin resistance (HOMA-IR), systolic blood
pressure (SBP), diastolic blood pressure (DBP), low-density lipopro-
tein (LDL), high-density lipoprotein (HDL), triglycerides, total
cholesterol, alanine transaminase (ALT), aspartate transaminase
(AST), gamma-glutamyl transpeptidase (GGT), albumin/creatinine
ratio (ACR), creatinine (Cr) and the echocardiographic ratio of early
to late ventricular filling velocities (E/A ratio).
2.6 | Quality and risk-of-bias assessment
The Cochrane risk-of-bias tool for randomised trials (RoB 2) tool was
used to assess for risk of bias.71 To determine the degree of confi-
dence in the effect of GLP-1RAs on our biomarkers of interest we
used the Grading of Recommendations Assessment, Development
and Evaluation (GRADEpro) tool.72
F IGURE 2 (Continued)
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2.7 | Statistical analysis
Participant characteristics are presented as weighted averages. Where
multiple doses were reported by the same article, a weighted average
was taken and combined for all relevant doses.61,69 Where mean and
SD were not available, SD was calculated from the standard error of the
mean (SEM), or values were estimated using methodology from the
Cochrane Handbook.73 Where median and interquartile range (IQR)
were provided, mean and SD were estimated with the widely used
methodology described by Wan et al, 2014.74 In the minority of cases
where the necessary SDs were not available, in the first instance, data
were sought from corresponding authors. Failing this, values were
imputed using validated methodology described by Ma et al, 2008.70
Trials were grouped based on comparability and analysed as subgroups.
Random effects meta-analyses were undertaken using Review Manager
(RevMan) 5.3, Copenhagen: Nordic Cochrane Centre, 2014. Mean dif-
ference (MD) was used for outcomes recorded using the same method,
and standard mean difference (SMD) for outcomes that were measured
using different methodology, each accompanied by 95% confidence
intervals [95% CI]. Heterogeneity was assessed using the I2 statistic and
F IGURE 2 (Continued)
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funnel plots were visually inspected for publication bias (Figure S1A-I).
Statistical tests were calculated using IBM SPSS (version 25). An α value
of <0.05 was considered significant. Sensitivity analysis was performed
to assess the robustness of the data analysed, eligibility criteria and
analysis methods. Dedicated software v. 2019b (Origin Lab, Northamp-
ton, Massachusetts) was used to produce graphs. "n" represents the
number of participants randomised.
3 | RESULTS
In accordance with the PRISMA checklist,29 our search of Medline,
Embase and the Cochrane Library identified 1702 articles (1061
inflammation, 641 oxidative stress; Figure 1). Of these, 40 RCTs
were found to be eligible (37 inflammation, 13 oxidative stress).
Included trials were published from 2008 to 2020 and the
majority were of a parallel design (37 parallel, three crossover).
They comprised 6749 patients (inflammation evaluated in 6560,
oxidative stress in 701 patients), included a median (IQR) study
population of 60 (33-122) participants, and had a median (IQR)
follow-up of 6 months (84-182 days). Trials recruited from 11 indi-
vidual countries and were multinational in four cases (14 from
China,30–33,37–39,41,44,47,48,56,58,65 seven from the United
States,36,52,53,59,61,63,68 three international studies,46,64,66 three
from Italy,49,62,67 three from Japan,45,55,57 two from Denmark,50,69 two
from Greece,42,54 two Sweden,34,35 one from France,51 one from
Germany,60 one from India,40 and one from Spain43). Participants had a
mean age of 53.1 years, 56.3% were women, the mean HbA1c was
55.6 (±8.89) mmol/mol, the mean BMI was 28.8 (±3.52) kg/m2. Partici-
pants had T2DM (39 trials) or prediabetes (three trials), and had a mean
diabetes duration of 7.46 (±4.22) years (Table 1). In 16 studies (20.8%
of total participants), both the active and control arms were also
receiving concomitant metformin,33,35,40,43,45,48,50–54,61–63,65,67
whereas the presence of concomitant medications was not clear in
11 studies (25.2% of total participants).30,32,36,38,39,44,47,56–58,64 In
three studies (5.8% of total participants) >50% of participants
received concomitant metformin and other diabetes medica-
tions.45,51,61 There were specific inclusion criteria in 14 trials includ-
ing overweight or obese participants,34,35,38,44–46,49,51,53,61,62,64,67,68
with three trials recruiting patients with coronary artery disease or
cardiovascular disease,35,47,53 two trials recruiting patients with
NAFLD30,31 and one study recruiting patients with albuminuria.50
The vast majority of trials either used liraglutide or exenatide
(liraglutide 22 trials, exenatide 14 trials, dulaglutide three trials,
taspoglutide one trial). Liraglutide was most often given as 1.8 mg
once daily and exenatide as 10 μg twice daily.
F IGURE 2 (Continued)
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3.1 | Risk-of-bias and quality assessment
Approximately one-third (33.8%) of all included trials were deemed to
be at high risk of bias using the Cochrane risk-of-bias tool (CRP
10/25, adiponectin 7/17, TNFα 5/11, IL-6 1/6, leptin 0/4, PAI-1 0/4,
MDA 2/3, 8-iso-PGF2α 0/4, and 8-OHdG 1/3; Table S2). Adherence
to intervention was flagged in 32.5% of included studies due to con-
cerns around blinding, with this reason alone causing 18/26 high risk
study results to be categorised as high risk. Concerns around selection
of results and randomisation contributed to the high risk of bias in
6.5% and 3.9% of trials, respectively. The quality of evidence was
graded as ‘moderate’ to ‘low’ (CRP moderate, adiponectin low, TNFα
low, IL-6 low, leptin low, PAI-1 low, MDA moderate, 8-iso-PGF2α
low, and 8-OHdG low; Table S3). In outcomes for which effect esti-
mates met significance (CRP, adiponectin, TNFα and MDA), grade was
reduced by risk of bias (mainly due to absence of blinding) and incon-
sistency as heterogeneity could not be fully explained by subgroup
analysis.
3.2 | Inflammatory biomarkers
As summarised in Table 2A, a pooled analysis of trials comparing GLP-
1RAs versus diabetes therapy or placebo (Total) showed significant
reductions in CRP and TNFα (MD 0.54 mg/L [0.75 to 0.34] I2
= 77%, P < 0.05; SMD 0.39 [0.62 to 0.15] I2 = 57%, P = 0.01,
respectively) and a significant increase in adiponectin (SMD +0.30
[0.12 to 0.49] I2 = 76%, P < 0.05 [Figure 2A-C]). Analysis of IL-6, lep-
tin and PAI-1, derived from fewer trials, showed nonsignificant,
negative trends (Figure 2D-F). Subgroup analyses reduced heteroge-
neity to nonsignificant levels in the majority of subgroups (64%) and
demonstrated that the GLP-1RAs versus routine diabetes therapy
subgroup contributed most to the effect estimate in CRP, adiponectin
and TNFα outcomes (MD 0.74 mg/L [1.06 to 0.43] I2 = 82%,
P < 0.05; SMD +0.42 [0.03 to 0.81] I2 = 73%, P < 0.05; SMD 0.60
[0.98 to 0.22] I2 = 37%, P > 0.05, respectively). Moreover, com-
parison of two trials of GLP-1RAs versus sitagliptin or glimepiride also
found that IL-6 was significantly reduced with GLP-1RA therapy.32,37
3.3 | Oxidative stress biomarkers
Pooled analysis of three trials (221 participants) comparing GLP-1RAs
versus metformin or insulin (Total) showed a strong and significant
reduction in serum MDA (SMD 0.84 [1.61 to 0.57] I2 = 87%,
P < 0.05 [Table 2B and Figure 2G]). There was no evidence of any
change in serum 8-iso-PGF2α or urinary 8-OHdG with use of GLP-
1RAs following pooled analyses (Figure 2H,I). Subgroup analyses
reduced heterogeneity in every subgroup to nonsignificant levels,
suggesting that the trials investigating change in MDA with GLP-1RAs
versus insulin were the main contributor to the effect estimate (SMD
1.19 [1.82 to 0.57] I2 = 69%, P > 0.05).
3.4 | Associated clinically relevant measurements
As expected, BMI was significantly reduced (n = 21, P < 0.0001) in the
included studies. Moreover, SBP was significantly lower in GLP-1RA-


















C-reactive protein 23 4962 0.54 mg/L† 0.75, 0.34 77 <.05 20 (80%) 15 (60%)
Adiponectin 17 3690 +0.30‡ 0.12, 0.49 76 <.05 11 (65%) 6 (35%)
Tumour necrosis factor-α 11 848 0.39‡ 0.62, 0.15 57 <.05 8 (73%) 5 (45%)
Interleukin-6 6 307 0.48‡ 1.22, 0.26 91 <.05 3 (50%) 1 (17%)
Leptin 4 376 0.44‡ 1.02, 0.15 85 <.05 2 (50%) 1 (25%)
Plasminogen activator inhibitor-1 4 2502 5.16 ng/mL† 19.3, 8.97 79 <.05 3 (75%) 1 (25%)
(B) Oxidative stress biomarkers
Serum malondialdehyde 3 221 0.84‡ 1.61, 0.06 87 <.05 3 (100%) 3 (100%)
Serum 8-iso-prostaglandin F2 alpha 4 131 +0.17 pg/mL† 3.96, 4.30 80 <.05 2 (40%) 2 (40%)
Urinary 8-hydroxy-20-deoxyguanosine 2 172 +0.28‡ 0.55, 1.12 85 <.05 3 (100%) 2 (67%)
Note: ‘Total’ refers to a collective of all three subgroups per biomarker. Trials (n) refers to the number of trials shown in the meta-analysis. Results from all
inflammatory markers are from serum measurements. Columns reporting oxidative stress biomarker control-subtracted mean change and trials significance
include trials reporting both serum and urinary biomarkers. Trials with consistent control-subtracted mean changes refers to trials reporting results
consistent with the directionality of our meta-analysis effect estimate. Of these, the number of trials that report significant changes are reported in the
adjacent column. Further information is found in Table S4.
Abbreviations: CI, confidence interval; MD, mean difference†; SMD, standard mean difference‡.
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treated groups (n = 15, P < 0.05). Of note, the decrease in SBP was
associated with a strong and significant correlation with decrease in
CRP (n = 9, r = 0.777, P < 0.05 [Figure 3A]). Interestingly, in a small
number of trials, change in HOMA-IR was also strongly associated with
change in CRP (n = 6, r = 0.898, P < 0.05). Change in HbA1c was not
associated with changes in any of the inflammatory or oxidative stress
biomarkers, including CRP (Figure 3B). Furthermore, change in the fol-
lowing variables were also not associated with change in CRP: follow-
up duration; dose of GLP-1RA; BMI; fasting and postprandial glucose;
DBP; lipids (LDL, HDL, triglycerides and total cholesterol); liver markers
(ALT, AST and GGT); kidney markers (ACR and Cr); and E/A ratio.
3.5 | Sensitivity analyses
The aforementioned results withstood sensitivity analyses examining
the specific data analysed, eligibility criteria and analysis methods
(Table S5). Following removal of imputed data, changes in CRP,
adiponectin and TNFα in the GLP-1RA group compared with the con-
trol (Total) remained significant. Mean difference analysis of studies
with congruent measurement methodology and scale comparing GLP-
1RAs with control (Total) also remained significantly increased for
adiponectin and decreased for TNFα. Removal of unblinded studies
did not affect the significant reduction in CRP or TNF, or significant
increase in adiponectin, but did make MDA nonsignificant. This is
probably due to a lack of power caused by removal of studies.
4 | DISCUSSION
This systematic review and meta-analysis of randomised controlled
trials examined the effect of GLP-1RAs on biomarkers of low-grade
inflammation and oxidative stress to further understand the mecha-
nism behind the cardiorenal protective properties of GLP-1RAs. We
found that therapy with GLP-1RAs compared to standard diabetes
treatments or placebo was associated with significant reductions in
serum CRP, TNFα and MDA and a significant increase in adiponectin.
Additionally, SBP was significantly reduced and strongly correlated
with the reduction of the inflammatory biomarker CRP. Given the
absence of many inflammatory and oxidative stress biomarkers from
major cardiovascular and renal outcome trials, this study represents
an important synthesis of evidence to inform a deeper understanding
of mechanisms influencing the clinical impact of GLP-1RAs and devel-
opment of similar medications.
The mechanisms by which GLP-1RAs modify cardiovascular and
renal outcomes have been grouped into direct and indirect effects.
Whilst indirect effects such as improved glycaemic control are likely
to be important, glycaemic control alone does not fully explain the
reduction in cardiovascular mortality associated with GLP-1RAs.75
There is increasing evidence that GLP-1RAs act as modulators of
atherosclerosis,76 and their anti-inflammatory and antioxidant prop-
erties may contribute to this, as supported by laboratory stud-
ies.77,78 This review demonstrates that these properties remain true
within the clinical domain and extend beyond CRP to other bio-
markers of inflammation and oxidative stress. However, it was not
possible to directly link cardiorenal outcomes to biomarker changes.
Although this topic remains controversial, nevertheless there is evi-
dence to suggest that a reduction in elevated CRP79 and reactive
oxygen metabolites80 is associated with a reduction in major cardio-
vascular events. We observed that a reduction in CRP was corre-
lated with HOMA-IR. In observational studies, a reduction in
HOMA-IR was also associated with a reduction in CRP81 and cardio-
vascular risk.82 GLP-1RAs are known to reduce SBP in people with
T2DM,83 however, the mechanism underlying this effect remains
F IGURE 3 Graphs showing the correlation between c-reactive protein and systolic blood pressure (A) and glycated haemoglobin HbA1c (B),
with individual subgroups demarked. r, Pearsonʼs correlation coefficient
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unclear. Indeed, an association between raised serum CRP and
hypertension has been noted in numerous settings, consistent with
our data showing reduced SBP with lower CRP levels.84 We
observed that GLP-1RAs are associated with a reduction in TNFα;
elevated levels of TNFα have been implicated in endothelial dys-
function in laboratory experiments.85 Adiponectin has a complex
relationship with cardiovascular risk. Meta-analysis of observational
studies including people with and without T2DM did not show a
benefit of higher adiponectin levels on cardiovascular disease risk.86
However, in studies of populations with predominantly T2DM,
increased adiponectin was associated with a reduction in cardiovas-
cular disease risk.87,88
The present study provides a comprehensive overview of the
clinical evidence supporting anti-inflammatory effects of GLP-1RAs
and to our knowledge is the only systematic review examining their
effects on biomarkers of oxidative stress. Previous meta-analyses of
observational and randomised studies have demonstrated a reduc-
tion in CRP associated with GLP-1RAs,89,90 but this review is the
first to demonstrate that the anti-inflammatory effect of GLP-1RAs
extends to TNFα and adiponectin in 40 RCTs with robust sensitivity
analyses. Our results are generalisable to clinical medicine because
we included comparison with many diabetes treatments, as often
patients are on a plethora of therapeutics, whilst simultaneously cat-
ering for specific comparison through use of subgroup analysis. We
observed that the anti-inflammatory effects of GLP-1RAs on CRP
and TNFα remain apparent even when compared with other diabe-
tes medications. Furthermore, subgroup analysis suggested that
GLP-1RAs reduce IL-6 when compared with other standard diabetes
medications. Another strength of this review is our analysis of asso-
ciated clinically relevant variables that suggested a link between
reduction in SBP and the reduction in CRP with GLP-1RAs. There
were fewer trials reporting SBP and other inflammatory biomarkers,
which might explain the lack of association between SBP with other
inflammatory biomarkers.
In terms of limitations, because larger outcome trials did not
examine inflammatory and oxidative stress biomarkers, much of the
evidence described is from smaller trials with moderate risk of bias.
This is compounded by the short duration of follow-up in some of
these trials. Of note, trials that have included biomarkers as secondary
outcomes may not necessarily be sufficiently powered to detect
changes in biomarkers in isolation. However, considered together, our
results are more generalisable and emphasise the importance of an
overall synthesis of data, as presented here. One-third of trials were
considered to have high risk of bias. This was predominantly due to
absence of blinding that as an independent factor led to 69.2% of tri-
als being classed as ‘high-risk’ (Table S2). It is plausible to predict that
blinding of participants and investigators is unlikely to substantially
alter the quantitative results of inflammatory and oxidative stress bio-
marker assays. To manage missing data, we endeavoured to estimate
values and, if that was not possible, we imputed values. For example,
data reported as medians are likely to be positively skewed due to
confounding variables such as illness that may have been missed by
the exclusion criteria. However, we argue that conversion of median
to mean in this case is more likely to reflect the true effect of GLP-
1RAs because the mean value would be influenced less by the skew
produced by this confounding variable. Where imputation was neces-
sary, we employed the validated method described by Ma et al.70 The
studies requiring imputation of SDs tended to be larger and thus this
method is likely to have overestimated the SD for these trials.
This would lead to a more conservative overall effect estimate for our
results.
In conclusion, this aggregate level meta-analysis of low- to
moderate-quality RCTs is a clinically important synthesis in under-
standing the anti-inflammatory and antioxidant properties of GLP-
1RAs. The present analysis demonstrated a significant reduction in
CRP, TNFα, MDA and a significant increase in adiponectin follow-
ing the use of GLP-1RAs compared with standard diabetes treat-
ments in patients with impaired glucose tolerance. Moreover,
reduction in CRP appears to be correlated with a reduction in SBP.
Despite the lack of direct evidence from major cardiovascular and
renal outcome trials on inflammatory and oxidative stress bio-
markers, we believe that this review offers important insights that
will inform clinical use of GLP-1RAs and ongoing development of
similar medications.
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